Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488105 | 0.85 | FPR2 (0.33) | PPARDTSHRTP53TDP1CA12 | |
| SCHEMBL22856775 | 0.72 | MMP1 (0.37) | CA12CA1CA2CA9CYP2C19 | |
| SCHEMBL23488140 | 0.72 | MMP1 (0.37) | CA12CA1CA2CA9CYP2C19 | |
| SCHEMBL4486615 | 0.68 | — | — | |
| SCHEMBL13986850 | 0.68 | — | — | |
| SCHEMBL10889980 | 0.66 | TSHR (0.43) | PPARDTSHRTP53TDP1CA12 | |
| Fosamine SCHEMBL8535758 | 0.66 | TSHR (0.43) | PPARDTSHRTP53TDP1CA12 | |
| SCHEMBL1733288 | 0.66 | ALDH1A1 (0.43) | GAACYP3A4CYP2C19 | |
| SCHEMBL4453622 | 0.66 | TSHR (0.43) | PPARDTSHRTP53TDP1CA12 | |
| SCHEMBL89146 | 0.66 | ALDH1A1 (0.43) | GAACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084836-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | THE UNIVERSITY OF TOLEDO (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210171553-A1 | COMPOSITIONS USEFUL IN THERAPY OF AUTOPHAGY-RELATED PATHOLOGIES, AND METHODS OF MAKING AND USING THE SAME | THE UNIVERSITY OF TOLEDO (US) | 2021-06-10 | — | — | US | disclosed |
| US-10882831-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | THE UNIVERSITY OF TOLEDO (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084836-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | TFEB, SQSTM1, BECN1 | PPARD 1360/4885TSHR 3379/4885TP53 477/4885 |
| US-20210171553-A1 | COMPOSITIONS USEFUL IN THERAPY OF AUTOPHAGY-RELATED PATHOLOGIES, AND METHODS OF MAKING AND USING THE SAME | TFEB, BECN1, SQSTM1 | PPARD 2683/4885TSHR 3991/4885TP53 433/4885 |
| US-10882831-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | TFEB, BECN1, SQSTM1 | PPARD 2922/4885TSHR 3997/4885TP53 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.